🎉 M&A multiples are live!
Check it out!

Actuate Therapeutics Valuation Multiples

Discover revenue and EBITDA valuation multiples for Actuate Therapeutics and similar public comparables like Benevolent AI, Pharming, and Galapagos.

Actuate Therapeutics Overview

About Actuate Therapeutics

Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). It is developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3B, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion.


Founded

2015

HQ

United States of America
Employees

10

Financials

LTM Revenue n/a

LTM EBITDA n/a

EV

$163M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Actuate Therapeutics Financials

Actuate Therapeutics has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.

In the most recent fiscal year, Actuate Therapeutics achieved revenue of n/a and an EBITDA of -$27.3M.

Actuate Therapeutics expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Actuate Therapeutics valuation multiples based on analyst estimates

Actuate Therapeutics P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue n/a n/a XXX XXX XXX
Gross Profit n/a n/a XXX XXX XXX
Gross Margin NaN% NaN% XXX XXX XXX
EBITDA -$24.7M -$27.3M XXX XXX XXX
EBITDA Margin -Infinity% -Infinity% XXX XXX XXX
Net Profit -$20.2M -$24.7M XXX XXX XXX
Net Margin -Infinity% -Infinity% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Actuate Therapeutics Stock Performance

As of April 15, 2025, Actuate Therapeutics's stock price is $8.

Actuate Therapeutics has current market cap of $156M, and EV of $163M.

See Actuate Therapeutics trading valuation data

Actuate Therapeutics Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$163M $156M XXX XXX XXX XXX $-2.65

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Actuate Therapeutics Valuation Multiples

As of April 15, 2025, Actuate Therapeutics has market cap of $156M and EV of $163M.

Actuate Therapeutics's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.

Analysts estimate Actuate Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Actuate Therapeutics and 10K+ public comps

Actuate Therapeutics Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $163M XXX XXX XXX
EV/Revenue n/a XXX XXX XXX
EV/EBITDA -6.0x XXX XXX XXX
P/E -5.7x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF -7.5x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Actuate Therapeutics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Actuate Therapeutics Valuation Multiples

Actuate Therapeutics's NTM/LTM revenue growth is n/a

Actuate Therapeutics's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $2.5M for the same period.

Over next 12 months, Actuate Therapeutics's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Actuate Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Actuate Therapeutics and other 10K+ public comps

Actuate Therapeutics Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth n/a XXX XXX XXX XXX
EBITDA Margin n/a XXX XXX XXX XXX
EBITDA Growth 10% XXX XXX XXX XXX
Rule of 40 (SaaS-only) n/a XXX XXX XXX XXX
Revenue per Employee n/a XXX XXX XXX XXX
Opex per Employee $2.5M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue n/a XXX XXX XXX XXX
R&D Expenses to Revenue n/a XXX XXX XXX XXX
Opex to Revenue n/a XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Actuate Therapeutics Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics and Small Molecules comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Actuate Therapeutics M&A and Investment Activity

Actuate Therapeutics acquired  XXX companies to date.

Last acquisition by Actuate Therapeutics was  XXXXXXXX, XXXXX XXXXX XXXXXX . Actuate Therapeutics acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Actuate Therapeutics

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Actuate Therapeutics

When was Actuate Therapeutics founded? Actuate Therapeutics was founded in 2015.
Where is Actuate Therapeutics headquartered? Actuate Therapeutics is headquartered in United States of America.
How many employees does Actuate Therapeutics have? As of today, Actuate Therapeutics has 10 employees.
Who is the CEO of Actuate Therapeutics? Actuate Therapeutics's CEO is Mr. Daniel M. Schmitt.
Is Actuate Therapeutics publicy listed? Yes, Actuate Therapeutics is a public company listed on NAS.
What is the stock symbol of Actuate Therapeutics? Actuate Therapeutics trades under ACTU ticker.
When did Actuate Therapeutics go public? Actuate Therapeutics went public in 2024.
Who are competitors of Actuate Therapeutics? Similar companies to Actuate Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Actuate Therapeutics? Actuate Therapeutics's current market cap is $156M
Is Actuate Therapeutics profitable? Yes, Actuate Therapeutics is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.